Quantcast
Last updated on April 18, 2014 at 12:36 EDT

Latest Biologic Stories

2013-10-28 08:25:51

Budgets are Limiting Wider Prescribing of Biologics; However, Access Will Improve with the Launch of New Drugs and Biosimilars, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 28, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the rheumatoid arthritis (RA) armamentarium in Argentina and Mexico includes a wide range of premium-priced biologics. However,...

2013-10-24 12:26:15

EU5 Payers Agree that the Requirement for Direct Comparative Data Is Increasing in the Highly Competitive RA Market, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 24, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that results from the ADACTA trial, which showed that Roche's RoActemra is superior to AbbVie's Humira as a monotherapy in biologics-naive...

2013-10-22 23:04:59

Reportbuyer.com just published a new market research report: Charting the Biosimilar and Biobetter Development Pipeline (2013). London (PRWEB) October 22, 2013 If you need to understand the important biosimilar and biobetter drug developments worldwide then this report is critical. The promise of biosimilars has been great but beyond the first wave of products progress has been slow. With a number of high-value biologics, particularly monoclonal antibodies such as Herceptin, Avastin,...

2013-10-22 12:28:24

-- Proper naming of biosimilars key for patient access, safety -- LAKE FOREST, Ill., Oct. 22, 2013 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, said at the World Health Organization (WHO) today that biosimilar drugs should be given the same nonproprietary names as original biologics to ensure patient access and safe prescribing. Sumant Ramachandra, M.D., Ph.D., senior vice president and chief scientific officer,...

2013-10-22 08:31:23

SEOUL, South Korea, Oct. 22, 2013 /PRNewswire/ -- Samsung BioLogics today announced that Samsung BioLogics and F. Hoffmann-La Roche have entered into a long term strategic manufacturing agreement under which Samsung will manufacture Roche's proprietary commercial biologic medicines at its two manufacturing facilities in Incheon, South Korea, of which one is currently under construction. Terms of the agreement will not be disclosed, including financial terms and products to be...

2013-10-21 12:24:34

Efficacious Emerging Biologics and Entry of Oral Agents Will Increase Competition in the TNF-Alpha-Refractory Space, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 21, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the psoriasis drug market will experience substantial growth over the next decade as sales increase from $5.5 billion in 2012 to nearly $9.2...

2013-10-21 08:29:21

People on biologic or systemic drugs should only receive inactivated vaccines PORTLAND, Ore., Oct. 21, 2013 /PRNewswire-USNewswire/ -- National Psoriasis Foundation (NPF) Medical Board recommends that people with psoriasis and psoriatic arthritis only receive inactivated flu vaccines while on drugs that suppress the immune system. People should talk with their doctors about vaccinations before starting immunosuppressive treatments, such as biologic or systemic drugs, the medical board...

2013-10-17 12:27:45

Surveyed Physicians Report that Payer Hurdles are Not the Only Obstacles to Prescribing Xeljanz, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 17, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that approximately one-half of surveyed rheumatologists and payers report that they believe Pfizer's Xeljanz has a comparable effect on the signs and symptoms of...

2013-10-16 23:19:46

It’s not the first prediction that has been made about the market for generic forms of biopharmaceutical drugs, but according to Kalorama Information a multi-billion dollar market for biosimilars will arrive in the next five years. The healthcare organization says it’s in almost everyone’s interest - payors, governments, providers and patients seeking low-cost alternatives to the most expensive and effective therapies. New York, NY (PRWEB) October 16, 2013 It’s not the first...

2013-10-14 23:21:18

Reportbuyer.com just published a new market research report: PharmaPoint: Psoriasis - UK Drug Forecast and Market Analysis to 2022. London (PRWEB) October 14, 2013 Summary GlobalData has released its new Country report, “PharmaPoint: Psoriasis - UK Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmet needs. While physicians agree that biologics are relatively safe and effective,...